136 related articles for article (PubMed ID: 25632070)
1. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Chu QS; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M; Bramwell VB; Powers J; Seymour LK; Eisenhauer EA
Ann Oncol; 2015 May; 26(5):973-981. PubMed ID: 25632070
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Eigl BJ; North S; Winquist E; Finch D; Wood L; Sridhar SS; Powers J; Good J; Sharma M; Squire JA; Bazov J; Jamaspishvili T; Cox ME; Bradbury PA; Eisenhauer EA; Chi KN
Invest New Drugs; 2015 Aug; 33(4):969-76. PubMed ID: 25983041
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
Zorzi AP; Bernstein M; Samson Y; Wall DA; Desai S; Nicksy D; Wainman N; Eisenhauer E; Baruchel S
Pediatr Blood Cancer; 2013 Nov; 60(11):1868-74. PubMed ID: 23893953
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Yong WP; Goh BC; Soo RA; Toh HC; Ethirajulu K; Wood J; Novotny-Diermayr V; Lee SC; Yeo WL; Chan D; Lim D; Seah E; Lim R; Zhu J
Ann Oncol; 2011 Nov; 22(11):2516-2522. PubMed ID: 21385886
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
[TBL] [Abstract][Full Text] [Related]
9. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
10. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Novotny-Diermayr V; Sangthongpitag K; Hu CY; Wu X; Sausgruber N; Yeo P; Greicius G; Pettersson S; Liang AL; Loh YK; Bonday Z; Goh KC; Hentze H; Hart S; Wang H; Ethirajulu K; Wood JM
Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic activity of the histone deacetylase inhibitor SB939 on renal fibrosis.
Kang SW; Lee SM; Kim JY; Kim SY; Kim YH; Kim TH; Kang MS; Jang WH; Seo SK
Int Immunopharmacol; 2017 Jan; 42():25-31. PubMed ID: 27855304
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Munster PN; Thurn KT; Thomas S; Raha P; Lacevic M; Miller A; Melisko M; Ismail-Khan R; Rugo H; Moasser M; Minton SE
Br J Cancer; 2011 Jun; 104(12):1828-35. PubMed ID: 21559012
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
14. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Mastoraki A; Schizas D; Vlachou P; Melissaridou NM; Charalampakis N; Fioretzaki R; Kole C; Savvidou O; Vassiliu P; Pikoulis E
Mol Diagn Ther; 2020 Oct; 24(5):557-569. PubMed ID: 32696211
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Tang F; Choy E; Tu C; Hornicek F; Duan Z
Cancer Treat Rev; 2017 Sep; 59():33-45. PubMed ID: 28732326
[TBL] [Abstract][Full Text] [Related]
18. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
Schmitt T; Mayer-Steinacker R; Mayer F; Grünwald V; Schütte J; Hartmann JT; Kasper B; Hüsing J; Hajda J; Ottawa G; Mechtersheimer G; Mikus G; Burhenne J; Lehmann L; Heilig CE; Ho AD; Egerer G
Eur J Cancer; 2016 Sep; 64():74-82. PubMed ID: 27367154
[TBL] [Abstract][Full Text] [Related]
20. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
